Association between TP53 gene codon72 polymorphism and prostate cancer risk

Abstract

Background: TP53 gene polymorphism could increase risks of several kinds of cancer. But it remained controversial whether TP53 gene codon72 polymorphism was associated with the susceptibility to prostate cancer. Thus, we conducted a meta-analysis that evaluated the association between TP53 gene codon72 polymorphism and prostate cancer risk. Method: A comprehensive research was performed from PubMed, Embase, Web of Science and China National Knowledge Infrastructure (CNKI) up to December 31, 2018. A random effect model was used to evaluate the effect of the outcome. The statistical analyses were performed with Review Manager 5.3.0 and Stata 14.0. The sensitivity analysis and publication bias tests were also performed to confirm the reliability of this meta-analysis. Results: 22 studies included 3146 cases and 4010 controls were involved in this meta-analysis. Overall, no association was observed between TP53 gene codon72 polymorphism and prostate cancer risk (Arg vs Pro: odds ratio [OR] = 1.12, 95% confidence interval [CI] = 0.98–1.30; ArgArg vs ProPro: OR = 1.26, 95% CI = 0.90–1.75; ProPro vs ArgArg+ ArgPro: OR = 1.17, 95% CI = 0.86–1.57; ArgPro+ ProPro vs ArgArg: OR = 1.21, 95% CI = 0.97–1.51). Subgroup analyses, based on ethnicity, source of control and Hardy–Weinberg equilibrium (HWE) status, showed consistent results. Conclusion: The meta-analysis we performed showed that there was no association of TP53 gene codon72 polymorphism with prostate cancer risk.

The Impact of HMGB1 Polymorphisms on Prostate Cancer Progression and Clinicopathological Characteristics

“…Taken together, these results exhibit the variety of HMGB1 SNPs in different cancers, consistent with the oncogenic and tumor-suppressing dual roles of HMGB1 during tumor development and therapy [ 13 ]. Different ethnicities, epigenetic factors, or genetic susceptibility might be responsible for this phenomenon [ 53 , 54 ]. A limitation of our study is that we lack data on HMGB1 mRNA or protein expression in prostate cancer patients, so more detailed analyses and evaluations could not be performed.…”

Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease

“…The CAG and GGN trinucleotide repeat polymorphisms within the transactivation domain of the androgen receptor gene are one example of an extensively studied candidate, however evidence for association between repeat length and PrCa risk has been inconsistent and modest [ 39 , 40 , 41 , 42 , 43 , 44 ]. Several other variants, genes or pathways were also examined under this approach, including the androgen [ 45 ] and oestrogen [ 46 ] metabolic pathways, and TP53 gene [ 47 ]; again with inconsistent evidence of association and magnitude or direction of effect frequently reported between studies. Another widely investigated class of candidate was DNA repair genes, for which associations with overall, aggressive or young onset disease have been reported for a handful of genes including BRCA2 [ 48 , 49 , 50 , 51 , 52 ], BRCA1 [ 53 , 54 , 55 ], CHEK2 [ 56 ], and NBN [ 57 , 58 ].…”

Study on the Multitarget Mechanism and Active Compounds of Essential Oil from Artemisia argyi Treating Pressure Injuries Based on Network Pharmacology

“…It is upregulated when stimulated by various stimuli and participates in various pathological processes, closely related to inflammation, tumor occurrence, and development [ 26 , 27 ]. TP53 and PGR are tumor suppressor proteins, being a biomarker and prognostic predictor of cancers usually [ 28 – 31 ]. Recent studies have shown that TP53 plays an important role in regulating signaling pathways to maintain the health and function of skeletal muscle cells.…”